Advertisement
Person › Details
Axel Hoos (Scorpion Therapeutics Inc.)
Hoos, Axel (Scorpion Therapeutics 202108– CEO before GSK 201406 VP Oncology RnD + Head Immuno-Oncology)
Organisation | Scorpion Therapeutics Inc. | |
Former/major organisation | GSK (Group) | |
Product | cancer immunotherapy (immuno-oncology, I-O) | |
Product 2 | oncology | |
Record changed: 2023-04-05 |
Advertisement
More documents for Axel Hoos
- [1] Scorpion Therapeutics, Inc.. (1/13/22). "Press Release: Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets". Boston, MA....
- [2] Immunocore Ltd.. (8/20/18). "Press Release: Immunocore Announces Start of Phase I ImmTAC Study in Patients with Solid Tumours". Oxford & Conshohocken, PA....
- [3] Adaptimmune Therapeutics plc. (9/7/17). "Press Release: GSK Exercises Option Over SPEAR T-cell Therapy Program Targeting NY-ESO". Philadeliphia, PA & Oxford....
- [4] Immunocore Ltd.. (7/3/17). "Press Release: Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline". Oxford & Conshohocken, PA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top